Biocon shares rose 2.6% after the European Medicines Agency recommended its Pertuzumab biosimilar, Pebrilzo, for approval. This is the first biosimilar cleared under the regulator’s new tailored clinical process for breast cancer treatment. Investors are now tracking the final marketing authorization from the European Commission and the company’s ability to scale production.
Biocon shares rose 2.6% after the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Pebrilzo. This medicine is a biosimilar to Pertuzumab, a treatment used for HER2-positive breast cancer. The recommendation is a notable step for the company, as it is the first biosimilar to receive such support under the EMA’s updated tailored clinical approach for breast cancer drugs.
The final step for the company involves a review by the European Commission, which will decide on the official marketing authorization. If approved, Pebrilzo is expected to be used in combination with Trastuzumab and standard chemotherapy.
The company is also focused on its production capabilities. Its manufacturing facility in Malaysia recently gained approval for a second drug product line. This expansion is designed to double the manufacturing capacity and support commercial supplies, starting in the second quarter of the fiscal year 2027.
Financially, the company is adjusting its spending. As large capital projects are nearing completion and insulin capacity grows, the management aims to improve profit margins by using its current operational scale. The firm operates in a competitive market and is looking to expand its product portfolio, which includes treatments such as bAspart and bDenosumab.
Investors will track the final regulatory approval in Europe, the future rollout of the new drug, and how the company manages production and costs to protect its profit margins. The company's success will depend on the final regulatory outcome and its ability to compete effectively in the European market.